Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer

Final appraisal determination

Final appraisal determination document (PDF 279 KB)

Committee papers ACM2 (PDF 1.6 MB)

Committee papers ACM3 (PDF 5.4 MB)

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): DSU spec - assessing technologies that are not cost effective at a zero price

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): final matrix

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): appraisal consultation

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): appraisal consultation document information

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): evaluation report

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): final scope

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): matrix - February 2013

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): response to consultee and commentator comments on the provisional matrix of consultees and commentators

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): equalities impact assessment

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): provisional matrix (pre-referral) - January 2012

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): draft scope for consultation (pre-referral) - January 2012